Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 11, Pages 5314-5324
Publisher
American Society for Microbiology
Online
2011-09-07
DOI
10.1128/aac.00194-11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy and Safety of Efavirenz Dose Reduction to 200 mg Once Daily in a Caucasian Patient with HIV
- (2013) Salvador Cabrera Figueroa et al. CLINICAL DRUG INVESTIGATION
- Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
- (2010) Heather J. Ribaudo et al. JOURNAL OF INFECTIOUS DISEASES
- CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients
- (2010) Jun Chen et al. THERAPEUTIC DRUG MONITORING
- CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
- (2009) Awewura Kwara et al. AIDS
- Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients
- (2009) S. E. Cabrera et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
- (2009) Awewura Kwara et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
- (2009) Jackson K. Mukonzo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
- (2009) M Arab-Alameddine et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti
- (2009) Paul Leger et al. JOURNAL OF INFECTIOUS DISEASES
- Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
- (2009) David W. Haas et al. JOURNAL OF INFECTIOUS DISEASES
- In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
- (2009) Julia di Iulio et al. Pharmacogenetics and Genomics
- Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of Therapy
- (2009) Sofia A Pereira et al. THERAPEUTIC DRUG MONITORING
- Efavirenz–rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients
- (2008) Salvador E Cabrera et al. AIDS
- Successful Use of Reduced-Dose Efavirenz in a Patient with Human Immunodeficiency Virus Infection: Case Report and Review of the Literature
- (2008) Mauro S Torno et al. PHARMACOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now